Pulmonary Hypertension in Children: The Twenty-First Century

Pediatric Clinics of North America

Volumn 53, Issue 5, 2006, Pages 961-987

  Berger, Stuart ^a   Konduri, Girija G ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEROPROST; BONE MORPHOGENETIC PROTEIN 2; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROCOLLAGEN C PROTEINASE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; RHO KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNIPROST; VASCULOTROPIN; WARFARIN;

ANTICOAGULATION; CHROMOSOME 2Q; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; ERYTHEMA; GENE MUTATION; GENETICS; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; INCIDENCE; INFLUENZA VACCINATION; INJECTION PAIN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG TRANSPLANTATION; NONHUMAN; NONVIRAL GENE THERAPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEDIATRICS; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; SEDATION; SYMPTOM; THROMBOEMBOLISM; VASCULAR SMOOTH MUSCLE;

CHILD; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS;

EID: 33749371013     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2006.08.001     Document Type: Review

References (99)

1. Widlitz A., and Barst R. Pulmonary artery hypertension in children. Eur Respir J 21 (2003) 155-176
2. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
3. Loyd J.E., Primm R.K., and Newman J.H. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 129 (1984) 194-197
4. Loyd J.E., Atkinson J.B., Pietra G.G., et al. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Chest 98 (1986) 497-503
5. Newman J.H., Wheeler L., Lane K.B., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345 (2001) 319-324
6. Trembath R.C., and Harrison R. Insights into the genetic and molecular basis of primary pulmonary hypertension. Pediatr Res 53 (2003) 883-888
7. Loyd J.E., Butler M.G., Faroud T.M., et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 152 (1995) 93-97
8. Shaul P.W., Farrar M.A., and Magness R.R. Pulmonary endothelial nitric oxide production is developmentally regulated in the fetus and newborn. Am J Physiol 265 (1993) H1056-H1063
9. Brannon T.S., MacRitchie A.N., Jaramillo M.A., et al. Ontogeny of cyclooxygenase-1 and cyclooxygenase-2 gene expression in ovine lung. Am J Physiol 274 1 Pt 1 (1998) L66-L71
10. Dawes G.S., Mott J.C., Widdicomb J.G., et al. Changes in the lungs of the newborn lamb. J Physiol 121 (1953) 141-162
11. Cassin S., Dawes G.S., Mott J.C., et al. The vascular resistance of the foetal and newly ventilated lung of the lamb. J Physiol 171 (1964) 61-79
12. Velvis H., Moore P., and Heymann M.A. Prostaglandin inhibition prevents the fall in pulmonary vascular resistance as a result of rhythmic distension of the lungs in fetal lambs. Pediatr Res 30 (1991) 62-68
13. Abman S.H., Chatfield B.A., Hall S.L., et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 259 (1990) H1921-H1927
14. Tiktinsky M.H., and Morin III F.C. Increasing oxygen tension dilates fetal pulmonary circulation via endothelium-derived relaxing factor. Am J Physiol 265 1 Pt 2 (1993) H376-H380
15. Wojciak-Stothard B., and Haworth S.G. Perinatal changes in pulmonary vascular endothelial function. Pharmacol Ther 109 1-2 (2006) 78-91
16. Shaul P.W., and Wells L.B. Oxygen modulates nitric oxide production selectively in fetal pulmonary endothelial cells. Am J Respir Cell Mol Biol 11 4 (1994) 432-438
17. Shaul P.W., Campbell W.B., Farrar M.A., et al. Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J Clin Invest 90 6 (1992) 2147-2155
18. Konduri G.G., and Mattei J. Role of oxidative phosphorylation and ATP release in birth related pulmonary vasodilation in fetal lambs. Am J Physiol Heart Circ Physiol 283 4 (2002) H1600-H1608
19. Konduri G.G., Mital S., Gervasio C.T., et al. Purine nucleotides contribute to pulmonary vasodilation caused by birth related stimuli in the ovine fetus. Am J Physiol 272 (1997) H2377-H2384
20. Bloch K.D., Filippov G., Sanchez L.S., et al. Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period. Am J Physiol 272 3 Pt 1 (1997) L400-L406
21. Hanson K.A., Burns F., Rybalkin S.D., et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158 1 (1998) 279-288
22. Travadi J.N., and Patole S.K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 36 6 (2003) 529-535
23. Manchester D., Margolis H.S., and Sheldon R.E. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol 126 (1976) 467-469
24. Perkin R.M., Levin D.L., and Clark R. Serum salicylate levels and right to left ductus shunts in newborn infants with persistent pulmonary hypertension. J Pediatr 96 (1980) 721-726
25. Vanmarter L.J., Leviton A., and Allred E.N. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal anti-inflammatory drug consumption during pregnancy. Pediatrics 97 (1996) 658-662
26. Alano M.A., Ngougmna E., Ostrea E.M., et al. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 107 (2001) 519-523
27. Abman S.H., Shanley P.F., and Accurso F.J. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 83 (1989) 1849-1858
28. Morin F.C. Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in newborn lamb. Pediatr Res 25 (1989) 245-250
29. Shaul P.W., Yuhanna I.S., German Z., et al. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 272 (1997) L1005-L1012
30. Villamor E., Le Cras T.D., Horan M.P., et al. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol 272 (1997) L1013-L1020
31. Black S.M., Johengen M.J., and Soifer S.J. Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs. Pediatr Res 44 6 (1998) 821-830
32. Villanueva M.E., Zaher F.M., Svinarich D.M., et al. Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension. Pediatr Res 44 (1998) 338-343
33. Pearson D.L., Dawling S., Walsh W., et al. Neonatal pulmonary hypertension: Urea-cycle intermediates, nitric oxide production and carbamoylphosphate synthetase function. N Engl J Med 344 24 (2001) 1832-1838
34. Brennan L.A., Steinhorn R.H., Wedgwood S., et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ Res 92 6 (2003) 683-691
35. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336 (1997) 597-604
36. Pierce C.M., Krywawych S., and Petros A.J. Asymmetric dimethyl arginine and symmetric dimethyl arginine levels in infants with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 5 6 (2004) 517-520
37. Tzao C., Nickerson P.A., Russell J.A., et al. Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol 31 2 (2001) 97-105
38. Mueller C.F., Laude K., McNally J.S., et al. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 25 2 (2005) 274-278
39. Wedgwood S., Dettman R.W., and Black S.M. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 281 5 (2001) L1058-L1067
40. Landmesser U., Dikalov S., Price S.R., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111 8 (2003) 1201-1209
41. Konduri G.G., Ou J., Shi Y., et al. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 285 1 (2003) H204-H211
42. Nandi M., Miller A., Stidwill R., et al. Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation 111 16 (2005) 2086-2090
43. Steinhorn R.H., Albert G., Swartz D.D., et al. Recombinant human superoxide dismutase enhances the effect of inhaled nitric oxide in persistent pulmonary hypertension. Am J Respir Crit Care Med 164 5 (2001) 834-839
44. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 25 (2004) 2243-2278
45. Hoeper M.M., and Rubin L.J. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med 173 5 (2006) 499-505
46. Humbert M., Deng Z., Simonneau G., et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20 3 (2002) 518-523
47. Cool C.D., Rai P.R., Yeager M.E., et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 349 12 (2003) 1113-1122
48. Yuan J.X., and Rubin L.J. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111 5 (2005) 534-538
49. Harrison R.E., Berger R., Haworth S.G., et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111 4 (2005) 435-441
50. Machado R.D., James V., Southwood M., et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 111 (2005) 607-613
51. Yeager M.E., Golpon H.A., Voelkel N.F., et al. Microsatellite mutational analysis of endothelial cells within plexiform lesions from patients with familial, pediatric, and sporadic pulmonary hypertension. Chest 121 3 Suppl (2002) 61S
52. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108 (2001) 1141-1150
53. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98 (1998) 1400-1406
54. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
55. West J., Fagan K., Steudel W., et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94 (2004) 1109-1114
56. Grunig E., Dehnert C., Mereles D., et al. Enhanced hypoxic pulmonary vasoconstriction in families of adults or children with idiopathic pulmonary arterial hypertension. Chest 128 6 Suppl (2005) 630S-633S
57. Teichert-Kuliszewska K., Kutryk M.J., Kuliszewski M.A., et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 98 2 (2006) 209-217
58. Rabinovitch M., Keane J.F., Fellows K.G., et al. Quantitative analysis of the pulmonary wedge angiogram in congenital heart defects. Circulation 63 (1981) 152-164
59. Rich S., Kauffman E., and Levy P.S. The effect of high doses of calcium channel blockers on survival in pulmonary hypertension. N Engl J Med 327 (1992) 76-81
60. Fuster V., Peele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
61. Wagenvoort C.A., and Wagenvoort N. Pathology of pulmonary hypertension (1977), John Wiley and Sons, New York
62. Barst R.J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 98 (1986) 497-503
63. Barst R.J., Hall J.C., and Gersony W.M. Factors influencing survival among children with primary pulmonary hypertension treated with vasodilator agents. Circulation 78 Suppl 2 (1988) 293
64. Barst R.J. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pediatr Clin North Am 46 (1999) 331-345
65. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
66. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
67. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinol, a prostacyclin analogue, in patients with pulmonary artery hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
68. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
69. Max M., and Rossaint R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur J Pediatr 158 Suppl 1 (1999) S23-S26
70. Dahlem P., van Aalderen W.M., de Neef M., et al. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med 32 (2004) 1055-1060
71. Barst R.J., McGoon M., McLaughlin V., et al. Beroprost therapy for pulmonary artery hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
72. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary artery hypertension. N Engl J Med 346 (2002) 896-903
73. Barst R.J., Ivy D., Dingemanse J., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary artery hypertension. Clin Pharmacol Ther 73 (2003) 372-382
74. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary artery hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
75. Schulze-Neick I.L., Reader J.A., Shekerdemian L., et al. The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease. J Thorac Cardiovasc Surg 124 (2002) 435-441
76. Prendergast B., Newby D.E., Wilson L.E., et al. Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart 82 (1999) 505-508
77. Ivy D., Doran A., Claussen L., et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary hypertension receiving concomitant bosentan. Am J Cardiol 93 (2004) 943-946
78. Michelakis E., Tymchak W., Lien D., et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary artery hypertension: comparison with inhaled nitric oxide. Circulation 105 (2002) 2398-2403
79. Atz A., and Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91 (1999) 307-310
80. Schulze-Neick I., Hartenstein P., Li J., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108 Suppl 1 (2003) II167-II173
81. Atz A.M., Lefler A.K., Fairbrother D.L., et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crisis. J Thorac Cardiovasc Surg 124 (2002) 628-629
82. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360 (2002) 895-900
83. Rashid A., and Ivy D. Severe paediatric pulmonary hypertension: new management strategies. Arch Dis Child 90 (2005) 92-98
84. Mathur P.N., Powles R.C.P., Pugsley P.O., et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. Ann Intern Med 95 (1981) 283-288
85. Thilenius O.G., Nadas A.S., and Jockin H. Primary pulmonary vascular obstruction in children. Pediatrics 36 (1965) 75-87
86. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
87. Thoele D.G., Barst R.J., and Gersong W.M. Physiologic-based management of primary pulmonary hypertension in children and young adults. [abstract]. J Am Coll Cardiol 15 (1990) 242A Abstract
88. Nootens M.T., Berarducci L.A., Kauffman E., et al. Prevalence and hemodynamic implications of a patent foramen ovale in pulmonary hypertension. [abstract]. J Am Coll Cardiol 2 (1993) 402A Abstract
89. Kerstein D., Garofano R.O., Hsu D.T., et al. Efficacy of blade balloon atrial septostomy in advanced pulmonary vascular disease. [abstract]. Am Rev Respir Dis 145 (1992) A717 Abstract
90. Kerstein D., Levy P.S., Hsu D.T., et al. Blade balloon atrial septostomy improves survival in patients with severe primary pulmonary hypertension. Circulation 91 (1995) 2028-2035
91. Date H., Aoe M., Nagahiro I., et al. Improved survival after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg 128 6 (2004) 933-940
92. Barr M.L., Schenkel F.A., Bowdish M.E., et al. Living donor lobar lung transplantation: current status and future directions. Transplant Proc 37 9 (2005) 3983-3986
93. Nagaoka T., Fagan K.A., Gebb S.A., et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171 5 (2005) 494-499
94. Kao P.N. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127 4 (2005) 1446-1452
95. Taraseviciene-Stewart L., Scerbavicius R., Choe K.H., et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2006) Epub ahead of print
96. Zhao Y.D., Courtman D.W., Deng Y., et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 4 (2005) 442-450
97. Campbell A.I., Zhao Y., Sandhu R., et al. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 104 18 (2001) 2242-2248
98. McMurtry M.S., Archer S.L., Altieri D.C., et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115 6 (2005) 1479-1491
99. Sandoval J., Bauerle O., Gomez A., et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 25 (1995) 466-474